LoadingLoadingLoadingNet selling: insiders sold $1.2M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full results8 funds hold a position and insiders have been net selling.
Buys/Adds (2)
Squarepoint
$109.6M
added
Point72
$65.8M
added
Sells/Trims (1)
Millennium
$35.8M
trimmed
Sells (1)
Kingsley Lawrence D
$1.2M
sold
Top-trader positions in IDXX could not be loaded.
Hyperliquid positioning - not every stock is covered
Last report
Aug 4, 2026
Financial period
Q2 2026
Earnings per share
$3.93 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Oct 24, 2026
EPS expected
$3.37 to $3.91
Revenue expected
11 analysts
Last 30 days
Analysts cutting estimates
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 4, 2026 | $4.27 / $3.93Yahoo Finance | +8.54% beat | $1.22B No estimate | Unavailable |
| Mar 31, 2026 | May 5, 2026 | $3.47 / $3.41Yahoo Finance | +1.74% beat | $1.14B No estimate | Unavailable |
| Dec 31, 2025 | Feb 2, 2026 | $3.08 / $2.94Yahoo Finance | +4.81% beat | $1.09B No estimate | Unavailable |
| Sep 30, 2025 | Nov 3, 2025 | $3.40 / $3.15Yahoo Finance | +8.08% beat | $1.11B No estimate | Unavailable |
| Jun 30, 2025 | Aug 4, 2025 | $3.63 / $3.30Alpha Vantage | +10.00% beat | $1.11B No estimate | Unavailable |
| Mar 31, 2025 | May 1, 2025 | $2.96 / $2.84Alpha Vantage | +4.23% beat | $998.4M No estimate | Unavailable |
| Dec 31, 2024 | Feb 3, 2025 | $2.62 / $2.40Alpha Vantage | +9.17% beat | $954.3M No estimate | Unavailable |
| Sep 30, 2024 | Oct 31, 2024 | $2.80 / $2.69Alpha Vantage | +4.09% beat | $975.5M No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $1.11B | $1.09B | $1.14B | $1.22B |
| Cost of what it sold | $421.9M | $432.5M | $418.1M | $437.5M |
| Gross profit | $683.4M | $658.1M | $722.7M | $779.1M |
| What it spent | ||||
| Research and development | $63.4M | $66.8M | $65.8M | $65.4M |
| Sales and admin | $105.9M | $108.6M | $119.1M | $116.8M |
| Other operating costs | $159.2M | $167.1M | $175.3M | $171.3M |
| Total operating expenses | $328.5M | $342.5M | $360.2M | $353.5M |
| What was left | ||||
| Operating profit | $354.8M | $315.6M | $362.6M | $425.6M |
| Interest on debt | $10.7M | $10.5M | $7.7M | $10.2M |
| Profit before tax | $344.8M | $307.0M | $355.4M | $417.2M |
| Tax | $70.2M | $58.8M | $77.0M | $78.8M |
| Net profit | $274.6M | $248.2M | $278.4M | $338.4M |
| EBITDA | $392.1M | $356.2M | $400.9M | $468.5M |
This stock is trending upward, and looks overbought after a fast run-up.
Trend
Constructive
60 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
IDEXX Laboratories, Inc. (IDXX) Stock Forecasts
BullishOct 22ILMN Q3 Earnings Preview: Strong Clinical Demand May Lift Performance
Leans bullishOct 22IDEXX Laboratories, Inc. (IDXX) Stock forecasts
BullishOct 22Goldman Sachs starts coverage for IDEXX Laboratories stock at USD 740.00
BullishOct 20IDEXX Laboratories, Inc. (IDXX) Stock Price & News
Leans bullishOct 18ResMed Inc. (RMD) Stock Forecasts
Leans bullishOct 18IDEXX Laboratories, Inc. (IDXX) Stock forecasts
BullishOct 18IDEXX Laboratories stock trades with a 39.69 price-to-earnings ratio
NeutralOct 17